[Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects].
Renal cell carcinoma (RCC) is susceptible to immunomodulating therapies. This is proven by clinical responses to unspecific immunotherapy with cytokines. Understanding the mechanisms of antigen presentation and recognition by T cells enables us to expand T-cell clones which are capable of recognizing specific tumor-associated antigens (TAA). The use of dendritic cells (DC) in specific cellular immunotherapy could be beneficial because of their outstanding properties in antigen presentation and T-cell costimulation. In order to circumvent the escape of some tumor cells under T-cell pressure, polyvalent vaccination strategies should be developed. This goal can be achieved by either pulsing respective transfecting DC with tumor cell lysates, RNA or DNA libraries, or a pool of peptide antigens. Careful monitoring of the elicited T-cell response and quality assurance (GMP and GCP) are mandatory to establish a rationale for specific immunotherapy against RCC and to bring it from the bench to the bedside.
Ringhoffer
M
M
Abteilung Innere Medizin III, Medizinische Klinik und Poliklinik, Universitätsklinikum Ulm, Prittwitzstrasse 43, 89075 Ulm.
Gschwend
J E
JE
D019496:Cancer Vaccines / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive; D007680:Kidney Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology
D019496:Cancer Vaccines